HUTCHMED (China) Ltd annual report, Q4 FY2021

Business context and reporting period

HUTCHMED (China) Limited filed an audited Form 20-F for the fiscal year ended December 31, 2021—not a standalone 2021 fourth-quarter report. The filing does not provide clear Q4-only financial results. The company develops and commercializes oncology and immunology medicines and operates China-focused prescription-drug and consumer-health businesses through subsidiaries and joint ventures. Financial statements are prepared under U.S. GAAP.

During 2021, HUTCHMED launched or expanded the commercialization of its China-approved oncology drugs Elunate (fruquintinib), Sulanda (surufatinib) and Orpathys (savolitinib). It also sold its entire interest in non-core OTC joint venture Hutchison Baiyunshan on September 28, 2021.

Financial performance and liquidity

Revenue rose 56.2%. Oncology/Immunology revenue increased to $119.6 million from $30.2 million; Other Ventures revenue increased to $236.5 million from $197.8 million. The gross-margin improvement reflected a greater contribution from higher-margin Oncology/Immunology revenue. R&D spending rose 71.1%, reflecting expanded clinical programs and international operations. The company reported $157.4 million of undrawn bank facilities at year-end and said cash, short-term investments, expected operating cash flows and available facilities should fund operations, debt service and capital spending for at least 12 months.

FY 2021 investing cash outflow was $306.3 million, including net short-term investment purchases and a $15.0 million Epizyme warrant purchase, partly offset by $159.1 million of proceeds from the Hutchison Baiyunshan disposal. Financing cash inflow was $650.0 million, principally reflecting the April private placement and Hong Kong share offering. Capital expenditure was $16.8 million; contracted capital commitments were $44.2 million, primarily for the Shanghai manufacturing facility. Total current assets were $1,212.1 million and current liabilities $311.7 million at year-end.

Material changes, outlook and commentary

• Reported results included a $121.3 million pre-tax gain on the Hutchison Baiyunshan disposal; the company reported $82.9 million attributable to the Group after tax and non-controlling interests. This one-time gain materially affected the year’s results.
• Elunate revenue was $53.5 million, versus $20.0 million in 2020. Eli Lilly-reported in-market sales rose 111% to $71.0 million. Sulanda generated $11.6 million in-market sales, with approximately 4,800 new patients estimated to have been treated. Orpathys generated $11.3 million of company revenue from royalties and manufacturing fees; AstraZeneca reported $15.9 million of in-market sales.
• Shanghai Hutchison Pharmaceuticals, a non-consolidated 50%-owned joint venture, contributed $44.7 million of equity earnings, up from $33.5 million. HUTCHMED said $103.0 million of dividends were declared from its joint ventures in 2021. Joint-venture dividends are subject to partner approval and operating needs.
• Management cited the April 30, 2022 FDA goal date for surufatinib’s U.S. NDA review; required site and manufacturing inspections remained outstanding and could be affected by COVID-19 travel restrictions. The EMA review was also ongoing.
• Management expected FRESCO-2 global Phase III fruquintinib results in the second half of 2022 and planned to initiate the global Phase III savolitinib/Tagrisso SAFFRON study in mid-2022. The Shanghai plant’s small-molecule equipment installation was planned for late 2022, with GMP compliance targeted for late 2023.
• Sulanda entered China’s NRDL from January 2022 at a 52% discount to its 2021 self-pay price. Elunate’s NRDL inclusion was renewed for two years from January 2022, with a 5% discount versus its 2021 NRDL price. These access gains may support volume but involve pricing trade-offs.
• There is no formal consolidated revenue or earnings guidance in the filing. The company expects substantial ongoing R&D and commercialization spending and may need additional funding over time. It has never paid a dividend and does not currently plan to do so.

Risks, contingencies and unusual items

• HUTCHMED reported a net operating cash outflow of $204.2 million, and Oncology/Immunology remained loss-making. Continued investment depends on product uptake, development and regulatory outcomes, partner payments, joint-venture dividends and access to capital.
• The company highlighted China regulatory, legal, data-security and cross-border data-transfer risks. It also disclosed that its auditor was subject to a PCAOB determination of inability to inspect or investigate completely; under the law then in effect, U.S. trading restrictions or delisting could arise in 2024, potentially sooner if proposed legislation were enacted.
• COVID-19 did not materially affect research, clinical studies or commercial activities in 2021 according to the company, but FDA inspections in China were postponed. Other key risks include clinical-trial failure or delay, pricing and reimbursement pressure, product safety, third-party supply dependence and manufacturing capacity.
• HUTCHMED recorded a $12.5 million fair-value loss on its Epizyme warrant. A $15.0 million milestone from AstraZeneca for initiation of a Phase III NSCLC study was triggered in February 2022 and was receivable after year-end.
• The company reported no material pending legal proceedings against it. Separately, a Hong Kong arbitration award in favor of Hutchison Sinopharm against Luye Pharma Hong Kong was RMB253.2 million plus costs and interest; the company expected payment in 2022, but had not recognized the award as income at year-end.
• The auditor issued an unmodified opinion on the 2021 financial statements and internal control over financial reporting; management also concluded disclosure controls and internal controls were effective. The auditor identified expected-credit-loss allowances as a critical audit matter. The filing notes the auditor’s PCAOB inspection limitations.

Important facts for investors to verify

• Confirm that the investment question concerns FY 2021: this filing contains no clear Q4-only results.
• Reconcile the reported $167.0 million net loss with the $194.6 million loss attributable to HUTCHMED, and assess the $121.3 million disposal gain separately from recurring performance.
• Track operating cash use, the pace of R&D and commercialization spending, and whether product revenues, partner receipts and joint-venture dividends can sustain the stated 12-month liquidity outlook.
• Verify the outcome and timing of surufatinib regulatory reviews and inspections, FRESCO-2, the planned SAFFRON trial and the Shanghai plant build-out.
• Assess the commercial impact of NRDL discounts and confirm reported in-market sales against revenue recognized by HUTCHMED and its partners.
• Monitor PCAOB inspection access and any resulting U.S. listing restrictions, alongside evolving China data and regulatory requirements.